key: cord-1011080-nqe5j7bw authors: Yang, Cheng-Wei; Hsu, Hsing-Yu; Chang, Hsin-Yu; Lee, Yue-Zhi; Lee, Shiow-Ju title: Natural cardenolides suppress coronaviral replication by downregulating JAK1 via a Na(+)/K(+)-ATPase independent proteolysis date: 2020-06-25 journal: Biochem Pharmacol DOI: 10.1016/j.bcp.2020.114122 sha: bf32b81e89d7ee1ca8eb16e976d8b9c93a417d83 doc_id: 1011080 cord_uid: nqe5j7bw An unprecedented biological function of natural cardenolides independent of their membrane target Na(+)/K(+)-ATPase is disclosed. Previously, we reported that cardenolides impart anti-transmissible gastroenteritis coronavirus (anti-TGEV) activity through the targeting of Na(+)/K(+)-ATPase and its associated PI3K_PDK1_RSK2 signaling. Swine testis cells with Na(+)/K(+)-ATPase α1 knocked down exhibited decreased susceptibility to TGEV infectivity and attenuated PI3K_PDK1_RSK2 signaling. Herein, we further explored a Na(+)/K(+)-ATPase-independent signaling axis induced by natural cardenolides that also afforded significant anti-coronaviral activity for porcine TGEV and human HCoV-OC43. Using pharmacological inhibition and gene silencing techniques, we found that this anti-TGEV or anti-HCoV-OC43 activity was caused by JAK1 proteolysis and mediated through upstream activation of Ndfip1/2 and its effector NEDD4. This study provides novel insights into the pharmacological effects of natural cardenolides, and is expected to inform their future development as antiviral agents. membered lactone ring and have a plethora of biological activities. They are best known for their toxicity, which is due to their inhibition of the Na + /K + ATPase (or the Na + −K + pump) involved in the maintenance of ion concentrations in cells and neurotransmission, although they have found clinical utility for the treatment of cardiovascular problems. [1] . However, in addition to Na + /K + -ATPase, there are several other potential pharmacological targets of cardenolides, e.g. steroid receptors [1, 2] . Also, ouabain and digoxin are both antagonists of estrogen receptor (ER) that could be useful in the development of breast cancer drugs [1] ; ouabagenin, the hydrolysis product of ouabain, is a novel class of ligand for the liver X receptor (LXR) [2] ; and innovative derivatives of cardiotonic steroids (cardenolides and bufadienolides) that target Na + /K + -ATPase are under development for the optimization of their cardio therapeutic effects [3] [4] [5] [6] . Janus kinase 1 (JAK1) is a member of the JAK family of intracellular, nonreceptor tyrosine kinases; essential for signaling certain type I and type II cytokines or interferons [7, 8] . JAKs initiate responses to cytokine signaling and immunoregulation as well as inflammation; and JAK1 may contribute to hepatitis C virus (HCV)-mediated pathogenesis via cooperation with HCV nonstructural protein 5A (NS5A) activated signal transducer and activator of transcription 3 (STAT3) [9] . Although JAK/STAT pathway is well-documented to be mainly activated through interferons for antiviral host defenses, viruses have evolved strategies to escape from antiviral host defenses and/or also to exploit activation of non-canonic JAK/STAT pathway to promote viral pathogenesis [10] . In addition to inhibition in viral replication [11] , JAK1-signaling inhibition also suppresses tumor progression and metastasis [12] , and is currently a therapeutic strategy for inflammatory diseases, e.g. rheumatoid arthritis [13] . Recently, we reported that cardenolides exert potent anti-transmissible gastroenteritis coronavirus (anti-TGEV) activity, [14, 15] in part through augmenting a TGEV-induced and Na + /K + -ATPase-dependent phosphoinositide 3-kinase_ 3phosphoinositide-dependent kinase 1_ ribosomal S6 kinase 2 (PI3K-PDK1-RSK2) signaling axis [15] . Furthermore, the PI3K inhibitor LY294002 could restore only part of the TGEV activity inhibited by ouabain [15] ; and therefore other signaling axes are posited to co-exist with PI3K-PDK1-RSK2, and co-contribute to the anti-TGEV activity for ouabain. Thus, additional studies are needed to have a comprehensive knowledge for the underlying mechanisms of action of anti-TGEV cardenolides Herein, we disclose the results of further investigations into the underlying anti-TGEV mechanisms of natural cardenolides. We found natural cardenolides also downregulated Na + /K + -ATPase-independent JAK1_STAT1/3 activation to inhibit viral activities of porcine TGEV and human coronavirus OC43 (HCoV-OC43), and confirmed the co-existence of the Na + /K + -ATPase-independent JAK1 diminishment with the augmented activation of Na + /K + -ATPase-dependent PI3K_PDK1_RSK2 which was reported previously [15] . Both signaling axes of augmented PI3K and downregulated JAK1 contributed to the anti-TGEV activity of natural cardenolides. Finally, we determined that ouabain downregulated JAK1/STATs signaling, at least in part, via NEDD4 E3 ubiquitin protein ligase (NEDD4) family interacting protein 1/2 (Ndfip1/2) and NEDD4 mediated JAK1 proteolysis. Recently, TGEV was reported to activate the JAK_STAT pathway; [16, 17] and we reported that the PI3K inhibitor LY294002 restored only part of that TGEV activity inhibited by ouabain, reaching a plateau at high concentrations, whereas ouabain enhanced PI3K_PDK1 activation, was associated with Na + /K + -ATPase, and contributed to anti-TGEV activity [15] . Accordingly, we sought to determine whether any JAK family kinase is associated with the anti-TGEV activities of ouabain, in addition to the pathways previously screened [15] . TGEV was found to activate JAK1 (in terms of increasing phosphorylation at 6 h.p.i), but had no significant effect on the rate of phosphorylation of JAK2, JAK3 and Tyk2 ( Figure 1A ). This induction of JAK1 activation (phosphorylation) was profoundly diminished by ouabain treatment in a dose dependent manner ( Figure 1B ) and over the 6 h.p.i of TGEV infection ( Figure 1C) , as was the activation/phosphorylation of STAT1 and STAT3 ( Figure 1C) . Strikingly, the JAK1 protein level was significantly decreased by ouabain treatment with or without TGEV infection ( Figure 1C ). The natural cardenolides oleandrin, digoxin, digitoxin, and digitoxigenin, as well as BSAconjugated digoxin (digoxin-BSA) were also examined for their anti-TGEV effect, and all significantly downregulated JAK1 protein levels and phosphorylation levels of STAT1 and STAT3 with or without TGEV infection ( Figure 1D . Therefore, natural cardenolides are suggested to effectively diminish the endogenous JAK1 protein levels. The role of JAK1 in the anti-TGEV effect of ouabain was studied in ST cells engineered to be depleted in JAK1 using a gene silencing approach. When the JAK1 Figure 1C ; [17] ); and the JAK inhibitor CYT387 inhibited TGEV replication via diminishment of JAK2 activation in ST cells infected with TGEV [17] . Therefore, it is conceivable that CYT387 is capable of enhancing the anti-TGEV activity of ouabain, as manifested by a further decrease in TGEV N protein levels ( Fig. 3B-a) and viral yields/titers ( Figure 3B-b) . Therefore, the diminishment of JAK1 is associated with the anti-TGEV activity of ouabain. Previously, we reported that the enhancement of PI3K_PDK1 activation by ouabain (which contributed to its anti-TGEV activity) was dependent on Na + /K + -ATPase [15] . Here, we discovered another effector, JAK1, that was diminished by ouabain, and thus also contributed to this anti-TGEV activity ( Figure 3 ). Since Na + /K + -ATPase is the perceptive pharmacological target of ouabain [18] [19] [20] , we first dissected whether JAK1 diminishment by ouabain was associated with Na + /K + -ATPase. From RT-PCR analysis for mRNAs, only the 1 and 4 isoforms of Na + /K + -ATPase were found expressed in ST cells while 2 and 3 isoforms were detected to express in heart or brain tissues of mouse, which served as positive controls in RT-PCR for 2 and 3 isoforms ( Figure 4A ). Further gene silencing of 1 or 4 isoforms did not decrease the protein level of JAK1 in ST cells ( Figure 4B & 4C-a & 4C-b). Therefore, JAK1 diminishment by ouabain is not associated with Na + /K + -ATPase. Other cardiac steroids such as bufalin and two innovative Na + /K + -ATPase effectors (istaroxime, an inhibitor; and rostafuroxin, a modulator) [21, 22] were also examined for their effect on JAK1 diminishment ( Figure 4D Figure 4D ). This result indicated that the targeting or inhibition of Na + /K + -ATPase is not necessarily associated with JAK1 diminishment, as it is for the natural cardenolides (Figures 1 and 2) ( Figure 4D ). Thus, we conclude that the anti-TGEV activity of ouabain caused by its diminishment of JAK1 is independent of both Na + /K + -ATPase and ouabain enhanced PI3K_PDK1 signaling axis activation. Cardenolides are also known to interact with estrogen, glucocorticoid, and androgen receptors [1, 23, 24] , in addition to Na + /K + -ATPase. Accordingly, we investigated the role of these steroid receptors in ouabain-associated JAK1 diminishment. TGEV infected ST cells were treated with agonists or antagonists of glucocorticoid receptor (GR), ER, and androgen receptor (AR). We found that diindolylmethane (DIM), an AR antagonist, diminished TGEV N protein expression and significantly decreased the protein and phosphorylation levels of JAK1 ( Figure 5A ). Furthermore, in TGEV infected ST cells, the protease inhibitor MG132 could rescue JAK1 protein levels reduced by ouabain, but not DIM ( Figures 5B & 5C) . Moreover, the JAK1 mRNA level was not decreased by either ouabain or DIM as determined by RT-qPCR ( Figure 5D ). Therefore, both ouabain and the AR antagonist DIM exert anti-TGEV activity at least in part by downregulation of JAK1, but the respective mechanisms that underlie these effects are different. Ouabain-associated JAK1 diminishment is neither dependent on Na + /K + -ATPase, nor associated with GR, ER, or AR. A few ubiquitination proteases and phosphatases have been reported to mediate JAK1 degradation [25] [26] [27] , including Ndfip1/2 by activation of the proteolysis ligase NEDD4 [25] . We thus examined these potential effectors and found that Ndfip1/2 may mediate the ouabain induced JAK1 deregulation. Herein, we knocked down the expression of either Ndfip1 or Ndfip2 ( Figure 6A ) and found that depletion of either was able to significantly restore the downregulated JAK protein level caused by ouabain treatment ( Figure 6B ) Furthermore, the NEDD4 inhibitor Heclin was also able to significantly rescue the ouabain downregulated JAK1 in a dose dependent manner ( Figure 6C ). Ndfip1/2 were reported to activate the proteolysis ligase NEDD4 and thus cause the JAK1 degradation [25] . Therefore, we conclude that Ndfidp1/2 and NEDD4 are associated with ouabain induced JAK1 diminishment. Western blotting was performed as described [30, 31] figure 5D , the changes in mRNA expression levels were determined using the ΔΔCT method with actin housekeeping genes by qPCR. TRCN0000072224-TRC01) (Academia Sinica, Taiwan) respectively for specific gene silencing were prepared as described previously [14] . After validation of knockdown expression in Na + /K + -ATPase α1, Na + /K + -ATPase α4, JAK1, JAK2, TYK2, Ndfip1 or Ndfip2, the selected cells were used for the followed experiments. The end point dilution experiment was performed as described previously [14] . The statistical significance between the two groups was evaluated by the two-tailed unpaired Student's t test; * and ** were used to denote the statistical significance for p < 0.05, and p < 0.01 respectively. Our results suggest there is another cellular target of cardenolides in addition to Na + /K + -ATPase which is associated with the proteolysis of JAK1 in TGEV infected ST cells. We investigated this mechanism and found that JAK1 deregulation contributed to the anti-coronaviral activity of natural cardenolides and that the JAK1 proteolysis upon ouabain treatment is associated with Ndfip1/2, which interacts with and activates E3 ligase NEDD4 ( Figure 6 ). Our results suggest that ouabain treatment activates Ndfip1/2 and NEDD4, resulting in the proteolysis of JAK1, and thereby contributing to the Na + /K + -ATPase independent anti-TGEV or anti-HCoV-OC43 activity of ouabain ( Figures 1, 2 & 6) . Moreover, this Ndfip1/2 and NEDD4 mediated JAK1 diminishment by ouabain is endogenous, because ouabain and other natural cardenolides downregulated JAK1 regardless of whether or not the ST or HCT-8 cells were infected by coronaviruses (Figures 1& 2) . Furthermore, BSA-conjugated digitoxin, which is membrane impermeable [32] [33] [34] [35] and thus conceivably only bound to membrane Na + /K + -ATPase, also decreased the JAK1 phosphorylation and protein levels as ouabain did (Figures 1D & 2B) . The exact cellular target of the cardenolides is associated with Ndfip1/2-(NEDD4)-JAK1 and likely also a membrane protein, but remains to be identified. Strikingly, whereas the natural cardenolides and bufalin (a bufadienolide) could induce significant JAK1 diminishment, the two innovative Na + /K + -ATPase effectors istaroxin (an inhibitor) and rostafuroxin (a modulator) [21, 22] examined herein ( Figure 4D ) could not. This is presumably due to their structures, which lack a furan-2one/pyran-2-one moiety common to their parental or other cardenolides. However, both istaroxin and rostafuroxin were either highly potent inhibitor or modulator of Na + /K + -ATPase [21, 22] . Therefore, JAK1 diminishment by Na + /K + -ATPase inhibitors/antagonists may not arise from their targeting of Na + /K + -ATPase; and Na + /K + -ATPase independent JAK1 diminishment by natural cardenolides and bufadienolides could be the basis for their clinical benefits in the diseases they are used to treat. An emerging strategy in drug discovery is the influence of cellular protein degradation by the development of proteolysis-targeting chimeric molecules (PROTACs), heterobifunctional small molecules designed to incorporate a ligand for recruiting an E3 ligase, a linker, and another ligand to bind with the protein targeted for degradation. [36] . In this approach, the selected molecule is targeted and recruited to the E3 ligase for degradation with specificity and selectivity. Our finding that cardenolides caused JAK1 diminishment via activation of NEDD4 suppress coronaviral replication bolsters that the NEDD4 associated JAK1 degradation is a candidate subject for the development of a novel PROTAC; and therapeutic applications could be explored based on the property of JAK1 diminishment/inhibition of the cardenolides as antivirals. In conclusion, an unprecedented biological function of the cardenolides independent of their Na + /K + -ATPase membrane target has been discovered. Our study has yielded novel insight into the pharmacological effects of cardenolides, which may constitute the basis for future antiviral agents and PROTACs. supervised the experimental design, the interpretation of the data, and the composition of the manuscript. The authors declare no conflict of interest. Table 1 . Sequences of the oligonucleotides used for RT-PCR and RT-qPCR The doses of ouabain or were referred to the dose response in Figure 1B and those of CYT387 based on previous report [17] . *, P<0.05; **, P<0.01. Results shown are averages +/-SD from three independent experiments. The swine specific primer pairs (shown in Table 1 ) for ATP1A1-A4 were used. B. Depletion of ATP1A1 by gene silencing did not result in JAK1 inhibition in in ST cells. previous report or tests done for effective doses prior their applications herein [37] . N.S., no significance; *, P<0.05; **, P<0.01. Averages +/-SD, from three experiments, were shown below their respective western blot. previous report [38] . MLN4924, an NEDD8 inhibitor was used here in as a non-specific reference control and the concentrations used as reported [39] . *, P<0.05; **, P<0.01. Averages +/-SD, from three experiments, were shown below their respective western blot. Sodium/potassium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of antibreast cancer drugs? Breast cancer research and treatment Ouabagenin is a naturally occurring LXR ligand without causing hepatic steatosis as a side effect Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial Istaroxime: a new luso-inotropic agent for heart failure Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+-ATPase alterations in ouabain and adducin-dependent hypertension Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth Signaling by type I and II cytokine receptors: ten years after Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase Interferon Independent Non-Canonical STAT Activation and Virus Induced Inflammation. Viruses Directacting antivirals and host-targeting strategies to combat enterovirus infections. Current opinion in virology Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer inhibition in rheumatoid arthritis: efficacy and safety of baricitinib Identification of anti-viral activity of the cardenolides, Na+/K+-ATPase inhibitors, against porcine transmissible gastroenteritis virus The cardenolide ouabain suppresses coronaviral replication via augmenting a Na(+)/K(+)-ATPasedependent PI3K_PDK1 axis signaling Ouabain activates the Na-K-ATPase signalosome to induce autosomal dominant polycystic kidney disease cell proliferation Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-kappaB Activation for Comprehensive and Ultimate Inhibition of Cardiac glycosides: From molecular targets to immunogenic cell death Cardiac glycosides as novel cancer therapeutic agents Novel therapeutic applications of cardiac glycosides Istaroxime: A rising star in acute heart failure Ouabain-digoxin antagonism in rat arteries and neurones Interaction of digitalis and spironolactone with human sex steroid receptors Interaction of spironolactone and digitalis with the 5 alpha-dihydrotestosterone (DHT) receptor of rat ventral prostate Ndfip-mediated degradation of Jak1 tunes cytokine signalling to limit expansion of CD4+ effector T cells The ubiquitin-mediated degradation of Jak1 modulates osteoclastogenesis by limiting interferon-beta-induced inhibitory signaling SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus Novel small-molecule inhibitors of transmissible gastroenteritis virus c-Junmediated anticancer mechanisms of tylophorine Non-genomic action of the mineralocorticoid aldosterone on cytosolic sodium in cultured kidney cells A specific membrane binding protein for progesterone in rat brain: sex differences and induction by estrogen Genomic and nongenomic effects of glucocorticoids Nongenomic glucocorticoid receptor action regulates gap junction intercellular communication and neural progenitor cell proliferation PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery The canine papillomavirus and gamma HPV E7 proteins use an alternative domain to bind and destabilize the retinoblastoma protein Peptide and small molecule inhibitors of HECT-type ubiquitin ligases An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer GTACTTCCACGGTAATACTA a m: mouse; b p: porcine; c for RT-qPCR